miR-137:阿尔茨海默病的治疗候选者或关键分子调节器?
Muhammad Wasim1, Junhao Guo2, Zhendong Wang1
1Maternal and Children's Health Research Institute, Shunde Women and Children's Hospital, Guangdong Medical University, Foshan, China.
Journal of Alzheimer's disease reports
|June 27, 2025
概括
微RNA-137 (miR-137) 是阿尔茨海默病 (AD) 的关键调节剂,影响粉样β和病理. 本综述探讨了miR-137作为诊断生物标志物和AD治疗点的潜力.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 阿尔茨海默病 (AD) 的特点是粉样β斑块,团,和突触损失.
- 微RNAs (miRNAs) 是小型非编码RNAs,它们调节基因表达,并与神经退行性疾病有关.
- miR-137是一种特定于大脑的miRNA,已成为AD病变发生的一个重要因素.
研究的目的:
- 审查miR-137在阿尔茨海默病中的多方面的作用.
- 探索miR-137作为诊断生物标志物和阿尔茨海默病的治疗点的潜力.
- 巩固关于miR-137分子机制和AD转化潜力的证据.
主要方法:
- 文献综述和现有研究的综合研究miR-137在AD.
- 生物信息分析以确定AD中miR-137调节的基因和网络.
- 对研究的分析,研究了阿尔茨海默病患者的循环miR-137水平.
主要成果:
- miR-137影响关键的AD病理,包括粉样β的产生,陶酸化,突触可塑性,神经炎症,线粒体功能和氧化应激.
- 循环中的miR-137水平与阿尔茨海默病的进展有相关性,这表明诊断效用.
- 生物信息分析显示,AD.中的miR-137调节的基因网络被破坏.
结论:
- miR-137是阿尔茨海默病的关键调节剂,影响多种病理途径.
- miR-137作为阿尔茨海默病诊断的非侵入性生物标志物和神经保护的治疗点具有显著的前景.
- 对miR-137的机制和治疗应用的进一步研究可能会彻底改变AD的管理.
相关概念视频
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
01:26Alzheimer's Disease: Overview
678
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
678
01:22MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
02:30siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K